Spotfire Plans 2001 Initial Public Offering | GenomeWeb

NEW YORK, Sept 19 – Spotfire, a developer of analytics software used by pharmaceutical and biotechnology companies, is considering an initial public offering on the Nasdaq next year.

Chris Ahlberg, Spotfire’s CEO, said the Cambridge, Mass.-based company expects to use money from an IPO for general business purposes. He declined to say how much the company hopes to raise.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.